Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an update.
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 35,544 new ordinary fully paid shares, to be issued on 27 January 2026 following the exercise or conversion of existing options or other convertible securities. The modest share issuance marginally increases the company’s quoted capital base and reflects ongoing utilisation of equity-linked incentives or financing structures, with limited immediate dilution for existing shareholders but signalling continued capital management activity as the company pursues its biopharmaceutical development objectives.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australian biopharmaceutical company listed on the ASX under the code PAR. The company operates in the life sciences industry, focusing on the development and commercialisation of pharmaceutical therapies, with its activities positioned within the broader healthcare and biotech markets.
Average Trading Volume: 861,900
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$140.9M
See more data about PAR stock on TipRanks’ Stock Analysis page.